Last reviewed 2026-04-22 · How we verify

AXS-14 (Esreboxetine)

Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron.

Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder, Treatment-resistant depression.

At a glance

Mechanism of action

By selectively inhibiting the norepinephrine transporter (NET), esreboxetine prevents the reuptake of norepinephrine from the synaptic cleft, leading to increased norepinephrine availability and enhanced noradrenergic neurotransmission. This mechanism is thought to improve mood, attention, and pain perception, making it potentially useful in depression and other neuropsychiatric conditions.

Approved indications

• Major depressive disorder
• Treatment-resistant depression

Common side effects

• Nausea
• Headache
• Insomnia
• Increased blood pressure
• Tachycardia

Key clinical trials

• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AXS-14 (Esreboxetine) CI brief — competitive landscape report
• AXS-14 (Esreboxetine) updates RSS · CI watch RSS
• Axsome Therapeutics, Inc. portfolio CI